Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

The most recent trading session ended with Merck (MRK) standing at $98.82, reflecting a -0.13% shift from the previouse trading day's closing. This move was narrower than the S&P 500's daily loss of 0 ...

The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees ...

During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he served as Managing Director ...

Exclusive-Kennedy Played Key Role in Vaccine Case Against Merck By Dan Levine and Mike Spector (Reuters) - Robert F. Kennedy ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

The five-year relative survival rate for DLBCL is 60-70%. This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning ...

RAHWAY, N.J., January 16, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference ...